Highly selective and potent SGLT2 inhibitors, such as dapagliflozin and canagliflozin, have demonstrated significant and clinically meaningful effects on glycemic control in T2DM patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.